Retrospective Cohort Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jan 24, 2025; 16(1): 93670
Published online Jan 24, 2025. doi: 10.5306/wjco.v16.i1.93670
Cohort study on the treatment of BRAF V600E mutant metastatic colorectal cancer with integrated Chinese and western medicine
Jiang-Yu Bian, Yu-Fang Feng, Wen-Ting He, Tong Zhang
Jiang-Yu Bian, Tong Zhang, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
Yu-Fang Feng, Department of Oncology, The Fourth Clinical Medical College of Xinjiang Medical University, Urumqi‎ 830001, China
Wen-Ting He, Department of Oncology, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi‎ 830001, China
Co-corresponding authors: Wen-Ting He and Tong Zhang.
Author contributions: Guarantor of integrity of entire study, manuscript preparation, manuscript definition of intellectual content, and manuscript final version approval were conducted by Zhang T; Study concepts, study design, and clinical studies were conducted by Zhang T and He WT; Literature research, data acquisition, and manuscript editing were conducted by Bian JY and Feng YF; Data analysis/interpretation was conducted by Zhang T and Bian JY; Statistical analysis and manuscript revision/review were conducted by He WT; Since this study includes two research centers in Beijing and Xinjiang, and the research workload of the two centers is balanced, He WT and Zhang T are listed as co-corresponding authors.
Supported by National Natural Science Foundation of China, No. 82174461; Hospital Capability Enhancement Project of Xiyuan Hospital, CACMS, No. XYZX0201-22; and Technology Innovation Project of China Academy of Chinese Medical Sciences; No. CI2021A01811.
Institutional review board statement: This study was approved by the Xiyuan Hospital, China Academy of Chinese Medical Sciences.
Informed consent statement: After review by the Ethics Committee, the informed consent was waived.
Conflict-of-interest statement: We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tong Zhang, MD, Associate Chief Physician, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China. ashtray7654@126.com
Received: March 3, 2024
Revised: September 4, 2024
Accepted: October 11, 2024
Published online: January 24, 2025
Processing time: 240 Days and 20 Hours
Core Tip

Core Tip: Patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) have a much lower median overall survival than patients without BRAF V600E mutations. This study employed a retrospective cohort design and confirmed that in the real world, compared to chemotherapy and/or targeted therapy, combined treatment with integrated Chinese and Western medicine significantly extended overall survival and reduced the risk of death in BRAF V600E mutated mCRC patients, while being more effective in patients involving right colon, liver metastases, combined chemotherapy, and first-line therapy.